Mannatech, Inc. — 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017; comparisons are with 2016. This is an annual report, not a standalone fourth-quarter filing. Mannatech sells nutritional, skin-care and weight-management products primarily through network marketing across three regions; China operations use cross-border e-commerce.
Financial performance and liquidity
| Metric | 2017 | 2016 |
|---|---|---|
| Net sales | $176.7 million | $180.3 million |
| Gross profit / margin | $141.0 million / 79.8% | $143.7 million / 79.7% |
| Operating income / margin | $2.5 million / 1.4% | $0.7 million / 0.4% |
| Income (loss) before taxes | $2.5 million | $(1.0) million |
| Net loss / diluted loss per share | $(1.8) million / $(0.66) | $(0.6) million / $(0.22) |
| Cash from operating activities | $10.0 million | $(0.02) million |
| Cash and cash equivalents at year-end | $37.7 million | $28.7 million |
| Working capital at year-end | $22.8 million | $20.8 million |
Gross margin was nearly flat. Net loss widened despite improved operating income, principally reflecting the $4.2 million income-tax provision in 2017. The filing reports provisional tax effects from the U.S. Tax Cuts and Jobs Act, including $0.8 million of deferred tax expense for remeasurement and $1.7 million of transition-tax expense, after foreign tax credits.
Investing activities used $1.3 million and financing activities used $3.1 million, including $1.4 million of dividends, $1.6 million of capital-lease repayments and $0.2 million of share repurchases. Year-end current liabilities were $33.4 million against current assets of $56.2 million. Debt-like obligations included $0.8 million of notes payable and $0.4 million of capital-lease obligations. Management said existing liquidity and operating cash flows should fund normal operations for the next 12 months; no formal earnings guidance was provided.
Material changes versus 2016
- Reported sales fell 2.0%; at constant currency, sales declined 3.3%. Favorable foreign exchange added $2.3 million to reported sales.
- Regional sales were $64.2 million in the Americas (down 8.5%), $98.8 million in Asia/Pacific (up 2.7%) and $13.7 million in EMEA (down 1.4%).
- Product sales rose 6.3% to $157.9 million, supported by average order value increasing to $182 from $166, although order count fell 4.1%.
- Pack sales and associate fees fell 46.8% to $14.2 million. Under the compensation-plan change introduced July 1, 2017, certain markets replaced product packs with annual associate fees. Packs sold and associate fees paid declined 16.5%; average pack value fell to $136 from $213.
- Active associate and preferred-customer positions declined to approximately 215,000 from 222,000. The Americas decline was partly offset by growth in Asia/Pacific.
- Operating expenses declined 3.2% to $138.5 million, including lower selling and administrative and other operating costs. Commissions and incentives were $74.6 million, or 42.2% of sales, versus $74.2 million, or 41.2%.
Outlook, risks and unusual items
- Management plans a second phase of compensation-plan adjustments in 2018 and expected to extend the shift from packs to associate fees to remaining markets. It cautioned that reduced pack sales could lower future sales volumes and that associate responses to plan changes are uncertain.
- Five product lines—Advanced Ambrotose, TruHealth, Manapol Powder, Ambrotose and PLUS—accounted for 54.5% of 2017 sales, up from 47.4%. Advanced Ambrotose alone contributed 29.8%.
- On November 14, 2017, the FDA issued a Warning Letter citing claims for BOUNCEBACK and labeling issues for other products. Mannatech said it removed the cited claims and submitted revised labels; it did not anticipate further action.
- Regulatory, product-claim and network-marketing compliance remain material risks, including potential responsibility for independent associates’ conduct. The company also highlighted intense competition, associate retention, foreign-exchange exposure and dependence on third-party suppliers. Arabinogalactan, used in Ambrotose, had no identified alternative supplier.
- A supply agreement requires $14.9 million of purchases through 2020. Other disclosed matters include an appeal of a Korean customs assessment previously paid ($1.0 million), a personal-injury case for which damages sought exceed $200,000, patent litigation and a trademark opposition. The filing says outcomes and potential liabilities for unresolved matters cannot be reliably predicted.
- The company held $30.6 million of cash in foreign bank accounts, including significant concentration in South Korea; it reported $32.7 million of net assets there. It does not use currency hedges.
- Operating cash flow improved substantially, partly alongside inventory reduction and changes in operating working capital. The 2017 cash increase also included a $3.4 million favorable currency-translation effect.
- The independent auditor gave an unmodified opinion on the financial statements. Management concluded internal control over financial reporting was effective; the auditor was not engaged to audit internal controls.
Key facts for investors to verify
- Whether the associate-plan transition improves retention, order activity and sales after the decline in active positions and pack-related revenue.
- Whether product-sales growth and margins can offset declining Americas revenue and continued concentration in a small number of products.
- Final tax accounting under the Tax Cuts and Jobs Act, including the provisional transition-tax estimate, repatriation plans and deferred-tax asset valuation allowances.
- Developments following the FDA Warning Letter and outcomes of pending litigation, customs and trademark matters.
- Cash-flow sustainability, foreign-cash accessibility, South Korea concentration and funding of the $14.9 million supplier commitment through 2020.